Colossal Biosciences has launched an AI platform, GenoMorph, to bridge data gaps in its de-extinction projects like the dodo. The tool identifies genetic targets using 3D biology, potentially speeding up gene-editing research. Backed by the new NeoGenesis Capital fund, the company aims to expand its synthetic biology technology into broader commercial sectors, including health and agriculture.
Colossal Biosciences is applying artificial intelligence to overcome data scarcity issues that have long slowed down its de-extinction efforts. The company recently launched a platform called GenoMorph, which uses comparative biology and 3D morphology to map genetic markers. This is particularly useful for projects like the dodo, where limited genetic material makes it difficult to understand which genes control specific physical traits.
GenoMorph functions by training AI models on a massive dataset of 3D skull measurements from over 70 bird species, alongside developmental data from modern birds like chickens and quail. By analyzing this information, the AI identifies critical gene-editing targets—the company has already isolated around 2,300 such targets for the dodo project. This allows researchers to focus their efforts on the most promising genetic regions rather than relying on time-consuming trial-and-error testing.
The company is also working to speed up the laboratory process. Traditionally, gene-editing tests in birds take years because researchers must wait for the animals to reach sexual maturity to observe the results of their modifications. Colossal is now using lipid nanoparticles to deliver gene-editing tools directly into avian embryos. This method significantly cuts down the waiting period, allowing researchers to observe the physical, or phenotypic, impact of these changes much faster.
From a business perspective, the focus is shifting from pure scientific research to practical, scalable technology. This transition is supported by the formation of NeoGenesis Capital, a new venture capital firm launched by Peter Diamandis, the founder of the XPRIZE. The fund is specifically set up to back companies that use Colossal's platform, signaling that investors see potential in applying these synthetic biology techniques beyond just bringing back extinct species.
While the immediate application is de-extinction, the core technology—AI-driven gene-editing and faster testing cycles—has potential implications for commercial biotechnology. Fields like health, agriculture, and environmental conservation are constantly seeking more efficient ways to perform genetic research. For the Indian biotechnology and life sciences sector, developments like these are important to watch as they highlight how artificial intelligence is moving from simple data analysis to complex biological engineering.
The company’s next steps will be critical to monitor, as they involve proving that these theoretical genetic models can translate into successful lab results. Industry observers will likely track how effectively these tools can be applied in commercial sectors and whether the company can maintain the current pace of its technological development in the coming quarters.